The SARS-CoV-2 –neutralizing capacity of kidney transplant recipients 4 weeks after receiving a second dose of the BNT162b2 vaccine
Coronavirus disease 2019 (COVID-19) –vaccinated kidney transplant recipients (KTRs) display a lower-than-normal antibody (Ab) response toward severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), indicating a reduced humoral immune response against the virus.1 A remaining question is to which extent this translates to lower the ability of KTRs to combat SARS-CoV-2.2 This capacity can be estimated by surrogate or pseudovirus neutralization assays or, optimally, the plaque reduction neutralization test (PRNT), in which live SARS-CoV-2 is challenged directly with patient blood plasma.
Source: Kidney International - Category: Urology & Nephrology Authors: Rune M. Pedersen, Line L. Bang, Ditte S. Tornby, Helene Kierkegaard, Anna C. Nilsson, Isik S. Johansen, Claus Bistrup, Th øger G. Jensen, Ulrik S. Justesen, Thomas E. Andersen Tags: Letter to the Editor Source Type: research
More News: Coronavirus | COVID-19 | Kidney Transplant | Kidney Transplantation | Respiratory Medicine | SARS | Transplant Surgery | Transplants | Urology & Nephrology | Vaccines